Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083376 | 0.78 | CYP1A2 (0.37) | ADORA2AADORA1CYP1A2LRRK2 | |
| SCHEMBL24238830 | 0.77 | LRRK2 (0.38) | ACHECYP1A2LRRK2 | |
| SCHEMBL25018457 | 0.76 | ADORA2A (0.41) | ADORA2AADORA1LRRK2 | |
| SCHEMBL23398734 | 0.76 | ALDH1A1 (0.33) | ACHEADORA2AADORA1CYP1A2 | |
| SCHEMBL17083396 | 0.73 | LRRK2 (0.35) | ACHEADORA2AADORA1LRRK2 | |
| SCHEMBL25680600 | 0.73 | — | — | |
| SCHEMBL25019042 | 0.72 | ADORA2A (0.37) | ACHEADORA2AADORA1CYP1A2LRRK2 | |
| SCHEMBL21719963 | 0.72 | — | — | |
| SCHEMBL17085012 | 0.72 | KDM4E (0.30) | — | |
| SCHEMBL25018708 | 0.71 | ADORA2A (0.33) | ACHEADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | ACHE 1176/4885ADORA2A 744/4885ADORA1 826/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | ACHE 1176/4885ADORA2A 744/4885ADORA1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.